Ex-Nightstar, Gyroscope and AGTC teams try again for next retinal gene therapy with $120M for Beacon Therapeutics

Life sci­ences in­vestor Syn­cona is tak­ing a sec­ond shot at X-linked re­tini­tis pig­men­tosa, this time with Bea­con Ther­a­peu­tics, a reti­nal gene ther­a­py start­up led by for­mer ex­ec­u­tives of Syn­cona-backed com­pa­nies Night­star Ther­a­peu­tics and Gy­ro­scope Ther­a­peu­tics. The…#nightstar #xlrp #biogen #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news